Business · 06/02/2006

FDA Refers ZINECARD and RELPAX Written Requests for Pediatric Studies to National Institutes of Health Foundation

The FDA has referred written requests for pediatric studies on ZINECARD (dexrazoxane) and RELPAX (eletriptan) to the National Institutes of Health Foundation, as mandated by the Best Pharmaceuticals for Children Act (BPCA), following a referral on August 29, 2005.